Introduction
============

Different therapy strategies are used to reduce spasticity in patients with traumatic spinal cord lesions. These options consist of conservative management, including physiotherapeutic and pharmacological approaches, as well as surgical techniques. Botulinum toxin plays an important role in the treatment of spasticity of different causes \[[@R1]\]. By locally injecting botulinum toxin, an isolated skeletal muscle inhibition and improved muscle kinematics can be achieved. Thus, botulinum toxin injection is a treatment option of particular interest in cases of localized spasticity \[[@R1]\], \[[@R2]\], \[[@R3]\].

The purpose of this study is to evaluate the effect of botulinum toxin injections in patients with spasticity caused by traumatic spinal cord injuries and to determine favourable patients' characteristic.

Materials and methods
=====================

The study included 9 male patients (mean age 40 y ± 16 y), suffering from a none-acute traumatic lesion of the spinal cord and chronic spastic paraplegia (Table 1 [(Tab. 1)](#T1){ref-type="fig"}). Eight patients had a complete spinal cord lesion, defined as American Spinal Injury Association (ASIA) impairment scale type A \[[@R4]\]. One patient showed an incomplete neurologic deficit, defined as ASIA type C. All of them offered an increased spasticity state of 3 to 4 on the Ashworth scale modified by Bohannon and Smith \[[@R5]\], \[[@R6]\]. All patients underwent a combination of physiotherapeutic and oral antispastic therapy for at least three months without satisfying success. Major spasticity affected not more than six general muscle groups of the lower limbs. All patients underwent botulinum toxin A injections in the affected muscle groups with a dilution of 100 U/ml under ultrasonographic control. The maximum general injection dose was limited to 2,000 U. After the injection, all patients underwent intensive physiotherapy of the affected muscles for three days to improve the Botox distribution. All patients underwent clinical control examinations after 3 ± 2 weeks and 34 ± 3 months after botulinum toxin injections.

Statistics
----------

A descriptive analysis was performed.

Results
=======

Six of the nine patients were satisfied or very satisfied after botulinum toxin injection and offered a clear reduction of spasticity in the treated muscle groups to a state of two or less on the Ashworth scale modified by Bohannon and Smith, with an average reduction of 1.9 states after two weeks (Figure 1 [(Fig. 1)](#F1){ref-type="fig"}). Five of them reported reduced difficulties during mobilisation including transfers to the wheel chair as well as getting dressed or undressed. The patient with incomplete motor function deficit showed a relevant reduction of the adductor spasticity. However, he had increasing problems in walking due to additional muscle weakness for three months and regaining muscle strength over a period of another three months afterwards. Another patient reported a temporary general weakness after injection, which fully recovered after three days. Two patients experienced no benefit regarding their spasticity level.

The effect of the botulinum toxin injections started after two to five days and reached a peak after an average of two weeks. No signs of infection or allergic reaction were recordable, particularly at the side of injection. At the final evaluation, three patients had persistent low spasticity at the affected muscle groups of state two or less of the Ashworth scale modified by Bohannon and Smith. Three patients regained spasticity to a slightly lower level (≤3) compared to the initial level of spasticity (Figure 1 [(Fig. 1)](#F1){ref-type="fig"}). The beneficial effect lasted for at least seven months and decreased subsequently in all of them.

Discussion
==========

Several studies showed the beneficial effect of botulinum toxin to adults and children in cases of spasticity and demonstrated it to be safe even after repeated injections \[[@R7]\], \[[@R8]\]. However, Bakheit et al. described dose-dependent side-effects in 7% of the patients \[[@R9]\]. The side-effects consisted of focal or generalized muscle weakness and urinary incontinence in about 1% of patients. All other reported adverse events were less common and included pain at the site of the injection, fatigue, somnolence, influenza-like symptoms, fever, and purpuric skin rash. Similarly, one of our patients (11%) complained of mild systemic weakness after injection, lasting for three days. Adverse effects were recorded after administering doses of more than 1,000 U in children and more than 2,000 U in adults \[[@R9]\]. Therefore, our maximal dose of administration was 2,000 U for each adult patient.

The encouraging results of our study are consistent with other studies that showed beneficial effects of botulinum toxin injections in the therapy of spasticity \[[@R1]\], \[[@R2]\], \[[@R3]\], \[[@R10]\]. Similarly, two case reports showed a positive effect of botulinum toxin injections in patients with spinal cord injury and ulcers caused by spasticity \[[@R11]\], \[[@R12]\].

In our study population, 6 of 9 of the patients presented with a significant reduction in their spasticity, reported a better quality of life, and were satisfied or very satisfied. Two of our patients did not benefit from the therapy. One of these patients showed a diffuse pattern of spasticity that affected six functional muscle groups of the upper and lower leg. Thus, this patient seemed to be a poor candidate for this treatment strategy based on the restricted maximal dose of botulinum toxin. Furthermore, this therapy has to be seen very critically in incomplete paretic patients (ASIA C), particularly in those who are able to walk. These patients are commonly dependent on maximum strength of all functional muscle groups at their lower limb. Thus, botulinum toxin injection causes weakness of certain muscle groups, which might lead to temporary immobilisation as seen in one of our cases.

The strong limitation of this study is its limited patient group, including only nine patients and only one patient with incomplete motor function deficit (ASIA C). Thus, certain patients' characteristics which might cause limited effectiveness of botulinum toxin injections, such as diffuse spasticity pattern or incomplete motor function deficit are based on single cases only. Thus, the statistics was based on descriptive analysis only. Additionally, the level of spasticity was based on the Ashworth scale modified by Bohannon and Smith that is purely observer dependent, which might lead to bias.

Nonetheless, this study includes a very selective patient collective with beneficial effects in the majority of the cases. Future studies are warranted to further evaluate the effects of botulinum toxin and the safety profile of it in the treatment of patients with spasticity after traumatic spinal cord injury.

Clinical messages
=================

Botulinum toxin injection for the treatment of spasticity after traumatic spinal cord lesion has the potential of a very promising treatment strategy.It seems to be particularly effective in patients with complete lower limb motor function deficit and spasticity pattern limited to few muscle groups.Caution has to be recommended in incomplete paretic patients, who are still able to walk, in order to avoid immobilizing effects.Further studies are necessary to find parameters, which might affect the antispastic therapy with botulinum toxin.
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